Detalhe da pesquisa
1.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Invest New Drugs
; 39(6): 1577-1586, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180036
2.
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Cancer Chemother Pharmacol
; 93(3): 177-189, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38010394
3.
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
Blood
; 112(8): 3434-43, 2008 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18474728
4.
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Cancer Res
; 80(2): 304-318, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31732654
5.
p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
Anticancer Res
; 28(6A): 3827-33, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19189670
6.
Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
PLoS One
; 13(6): e0199361, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29928062
7.
Effective implementation of novel MET pharmacodynamic assays in translational studies.
Ann Transl Med
; 5(1): 3, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28164088
8.
Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays.
Clin Cancer Res
; 22(14): 3683-94, 2016 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27001313
9.
p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
Oncogene
; 23(54): 8766-76, 2004 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-15480425
10.
Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.
Leuk Lymphoma
; 49(10): 1963-75, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18949619
11.
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.
Blood
; 108(13): 4170-7, 2006 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16940419
12.
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
J Pharmacol Exp Ther
; 318(1): 99-107, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16603672
13.
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Exp Cell Res
; 312(10): 1909-23, 2006 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-16600214
14.
APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA.
J Immunol
; 172(1): 138-43, 2004 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14688319